IMP Accountability refers to the process of tracking and documenting the lifecycle of an Investigational Medicinal Product (IMP) throughout a clinical trial. This includes maintaining accurate records of the receipt, storage, dispensing, administration, return, and disposal of the IMP at all stages of the study.
The purpose of IMP Accountability is to ensure regulatory compliance, patient safety, and data integrity in clinical research. It helps investigators and sponsors demonstrate that the IMP was handled correctly and administered only to eligible study participants in accordance with the approved protocol.
IMP Accountability is crucial for maintaining the integrity and validity of clinical trial results. It ensures that the investigational product is used as intended, minimizing the risk of errors that could compromise patient safety or study outcomes. Proper accountability also helps detect and prevent potential fraud or misconduct in clinical research.
Furthermore, IMP Accountability is essential for regulatory compliance and auditing purposes. It provides a clear trail of evidence that can be reviewed by regulatory authorities to verify adherence to Good Clinical Practice (GCP) guidelines. This documentation is vital for the approval process of new drugs and therapies, demonstrating the reliability of the clinical trial data.
Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…
Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
Copyright @ 2026 Axcellant|Privacy Policy|Cookie Policy|